{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-003666","form_type":"8-K","ticker":"RLYB","cik":"0001739410","company_name":"Rallybio Corp","filed_at":"2022-03-15T23:59:59+00:00","discovered_at":"2026-05-14T18:04:07.996825+00:00","generated_at":"2026-06-26T22:51:45.750442+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Rallybio reports Q4 2021 net loss of $12.4M; cash $175.3M; pipeline updates on RLYB212 and RLYB116","bullets":["Net loss of $12.4M ($0.42 per share) for Q4 2021; full year net loss $47.0M ($1.84 per share).","Cash and cash equivalents of $175.3M as of December 31, 2021.","R&D expenses $6.1M in Q4 2021 ($26.9M FY); G&A $6.2M Q4 ($18.7M FY).","Phase 1b proof-of-concept for RLYB212 (FNAIT) to start Q2 2022; initial data expected Q3 2022.","Phase 1 study of RLYB116 (C5 inhibitor) initiated; single dose safety/PK/PD data expected 2H 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-003666","json":"https://secwatch.observer/filing/0000950170-22-003666.json","markdown":"https://secwatch.observer/filing/0000950170-22-003666.md","text":"https://secwatch.observer/filing/0000950170-22-003666.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1739410/000095017022003666/0000950170-22-003666-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1739410/000095017022003666/rlyb-20220315.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T22:51:45.750442+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}